RYTM - Rhythm Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Boston,
United States
Type: Equity
RYTM price evolution
RYTM
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $162.13 | $53.89 | $60.41 | |
| Short term investments | $157.46 | $147.77 | $215.76 | |
| Net receivables | $19.31 | $17.6 | $14.7 | $14.87 |
| Inventory | $13.89 | $11.99 | $8.51 | $8.62 |
| Total current assets | $340.34 | $357.37 | $235.75 | $308.27 |
| Long term investments | ||||
| Property, plant & equipment | $4.39 | $4.67 | $1.82 | $2.12 |
| Goodwill & intangible assets | $6.6 | $6.82 | $7.03 | |
| Total noncurrent assets | $24.48 | $22.9 | $24.48 | |
| Total investments | $157.46 | $147.77 | $215.76 | |
| Total assets | $363.57 | $381.85 | $258.65 | $332.75 |
| Current liabilities | ||||
| Accounts payable | $4.89 | $4.54 | $7.55 | $4.88 |
| Deferred revenue | $1.29 | $1.29 | $1.29 | |
| Short long term debt | $0.82 | $0.79 | $0.77 | |
| Total current liabilities | $97.61 | $54.72 | $54.16 | $55.2 |
| Long term debt | $109.24 | $3.3 | $0.28 | $0.49 |
| Total noncurrent liabilities | $147.63 | $142.91 | $107.78 | |
| Total debt | $4.12 | $1.08 | $1.26 | |
| Total liabilities | $210.88 | $202.35 | $197.07 | $162.99 |
| Shareholders' equity | ||||
| Retained earnings | -$1112.01 | -$1068.37 | -$1036.11 | -$894.74 |
| Other shareholder equity | -$0.6 | -$0.62 | -$0.18 | $0.13 |
| Total shareholder equity | $39.34 | $61.58 | $169.76 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $60.41 | $128 | $59.58 | $101.26 |
| Short term investments | $215.76 | $205.61 | $235.61 | $71.94 |
| Net receivables | $14.87 | $6.22 | $1.02 | |
| Inventory | $8.62 | $2.92 | ||
| Total current assets | $308.27 | $354.24 | $308.39 | $181.67 |
| Long term investments | ||||
| Property, plant & equipment | $2.12 | $3.38 | $4.33 | $5 |
| Goodwill & intangible assets | $7.03 | $7.88 | $4.66 | |
| Total noncurrent assets | $24.48 | $28.25 | $21.14 | $5.41 |
| Total investments | $215.76 | $205.61 | $235.61 | $71.94 |
| Total assets | $332.75 | $382.48 | $329.52 | $187.07 |
| Current liabilities | ||||
| Accounts payable | $4.88 | $4.8 | $5.74 | $4.9 |
| Deferred revenue | $1.29 | $1.43 | ||
| Short long term debt | $0.77 | $0.68 | $0.61 | $0.54 |
| Total current liabilities | $55.2 | $39.81 | $43.43 | $17.99 |
| Long term debt | $0.49 | $75.81 | $1.95 | $2.55 |
| Total noncurrent liabilities | $107.78 | $78.41 | $1.95 | $2.55 |
| Total debt | $1.26 | $1.94 | $2.55 | $3.09 |
| Total liabilities | $162.99 | $118.22 | $45.37 | $20.55 |
| Shareholders' equity | ||||
| Retained earnings | -$894.74 | -$710.06 | -$528.94 | -$459.33 |
| Other shareholder equity | $0.13 | -$0.09 | -$0 | $0.05 |
| Total shareholder equity | $169.76 | $264.26 | $284.15 | $166.53 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $33.25 | $29.08 | $25.97 | $24.23 |
| Cost of revenue | $2.95 | $2.81 | $3.23 | |
| Gross Profit | $29.42 | $26.13 | $23.16 | $21 |
| Operating activities | ||||
| Research & development | $30.19 | $128.66 | $29.89 | |
| Selling, general & administrative | $36.41 | $34.38 | $32.37 | |
| Total operating expenses | $73.31 | $66.61 | $163.05 | $62.27 |
| Operating income | -$40.48 | -$139.89 | -$41.27 | |
| Income from continuing operations | ||||
| EBIT | -$27.18 | -$136.32 | -$36.89 | |
| Income tax expense | -$0.34 | $0.48 | $0.3 | $0.2 |
| Interest expense | -$1.19 | $4.6 | $4.75 | $4.55 |
| Net income | ||||
| Net income | -$44.97 | -$32.26 | -$141.37 | -$41.63 |
| Income (for common shares) | -$33.56 | -$141.37 | -$41.63 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $77.43 | $23.64 | $3.15 | |
| Cost of revenue | $9.3 | $2.13 | $0.6 | |
| Gross Profit | $68.13 | $21.5 | $2.56 | |
| Operating activities | ||||
| Research & development | $134.95 | $108.63 | $104.13 | $90.45 |
| Selling, general & administrative | $117.53 | $92.03 | $68.49 | $46.13 |
| Total operating expenses | $252.48 | $200.66 | $172.61 | $136.57 |
| Operating income | -$184.36 | -$179.16 | -$170.06 | -$136.57 |
| Income from continuing operations | ||||
| EBIT | -$170.22 | -$175.92 | -$69.61 | -$134 |
| Income tax expense | $0.56 | |||
| Interest expense | $13.89 | $5.2 | ||
| Net income | ||||
| Net income | -$184.68 | -$181.12 | -$69.61 | -$134 |
| Income (for common shares) | -$184.68 | -$181.12 | -$69.61 | -$134 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$32.26 | -$141.37 | -$41.63 | |
| Operating activities | ||||
| Depreciation | $0.39 | $0.41 | $0.42 | |
| Business acquisitions & disposals | -$40 | |||
| Stock-based compensation | $10.36 | $7.77 | $8.67 | |
| Total cash flows from operations | -$29.08 | -$40.74 | -$29.38 | |
| Investing activities | ||||
| Capital expenditures | $0 | |||
| Investments | -$8.56 | $70.05 | $22.64 | |
| Total cash flows from investing | -$69.33 | -$8.56 | $30.05 | $22.64 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.4 | $7.03 | $5 | |
| Net borrowings | ||||
| Total cash flows from financing | $152.91 | $146.18 | $4.24 | $2.42 |
| Effect of exchange rate | -$0.97 | -$0.3 | -$0.07 | -$0.19 |
| Change in cash and equivalents | -$12.43 | $108.24 | -$6.52 | -$4.51 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$184.68 | -$181.12 | -$69.61 | -$134 |
| Operating activities | ||||
| Depreciation | $1.76 | $1.67 | $1.16 | $0.69 |
| Business acquisitions & disposals | -$5.67 | |||
| Stock-based compensation | $32.55 | $19.83 | $20.8 | $17.45 |
| Total cash flows from operations | -$136.16 | -$173.43 | -$146 | -$121.98 |
| Investing activities | ||||
| Capital expenditures | -$0.05 | -$0.28 | $99.57 | -$0.21 |
| Investments | $0.05 | $32.31 | -$163.72 | $158.75 |
| Total cash flows from investing | -$5.67 | $28.03 | -$62.16 | $158.53 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $57.4 | $141.49 | $166.48 | $2.01 |
| Net borrowings | $24.37 | $72.34 | ||
| Total cash flows from financing | $74.37 | $213.83 | $166.48 | $2.01 |
| Effect of exchange rate | -$0.14 | |||
| Change in cash and equivalents | -$67.6 | $68.43 | -$41.68 | $38.56 |
News
Fundamentals
| Market cap | $6.70B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 61.44M |
| Revenue | $112.53M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$260.24M |
| Revenue Q/Q | 47.76% |
| Revenue Y/Y | 81.55% |
| P/E ratio | -25.76 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 59.57 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$4.24 |
|---|---|
| ROA | -77.87% |
| ROE | N/A |
| Debt/Equity | 0.96 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.49 |
| Quick ratio | 3.34 |